Faculty Bibliography

BACKGROUND/UNASSIGNED:Arthrofibrosis represents a source of patient dissatisfaction following total knee arthroplasty (TKA). The purpose of this systematic review and meta-analysis was to evaluate the efficacy of perioperative angiotensin II receptor blockers (ARBs) as anti-fibrotic agents in patients undergoing total knee arthroplasty (TKA). METHODS/UNASSIGNED:The Medline, Embase and Cochrane library databases were systematically reviewed using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The outcome measures of interest were postoperative knee range of motion (ROM), rates of manipulation under anesthesia (MUA) and revision rates. RESULTS/UNASSIGNED: = 0.3349). CONCLUSION/UNASSIGNED:This systematic review and meta-analysis found that the utilization of perioperative ARBs were not associated with superior postoperative knee ROM nor lower rates of MUA in patients undergoing TKA. Additionally, no difference in revision TKA rates existed between patients in the ARB cohort compared to the control cohort. Based on the current available data, it is the author's current recommendation that perioperative ARB usage is not indicated in the setting of TKA for the prevention of arthrofibrosis. However, this analysis should be interpreted in light of the low level of evidence and under-reporting of data of the included studies. Thus, higher-level evidence, prospective, comparative studies should be conducted to definitively identify if perioperative ARBs can be utilized as effective anti-fibrotic agents in the setting of TKA.

BACKGROUND:Severe obesity and its association with advanced knee osteoarthritis are established risk factors for surgical complications and associated costs of total knee arthroplasty (TKA). This clinical trial examines the functional knee outcomes of severely obese patients who have severe knee osteoarthritis undergoing bariatric surgery versus immediate TKA and examines the impact of surgical weight loss on the pursuit of TKA. METHODS:The SWIFT Trial (Surgical Weight-loss to improve Functional status Trajectories) following total knee arthroplasty was a multicenter, prospective trial examining outcomes of weight loss surgery and TKA in patients who have severe obesity (body mass index ≥ 40 or greater than 35 who have comorbidities) and symptomatic Kellgren-Lawrence grades 3 or 4 radiographic knee osteoarthritis. Study patients were recruited prospectively from November 2015, to October 2024 and divided into two groups: the bariatric arm (patients undergoing bariatric surgery) and the TKA arm (patients undergoing TKA). Each study arm underwent a comprehensive battery of knee functional assessments at baseline, six, 12, and 24 months, as well as re-evaluations in the bariatric surgery arm to assess the need for delaying or proceeding with TKA at 12 and 24 months. There were 232 study subjects who completed surgery and knee evaluation (n = 159: immediate TKA versus n = 73: bariatric surgery). The study groups had comparable degrees of knee disability at study initiation. RESULTS:Longitudinal functional analysis demonstrated major improvement extending to two years in patient-reported outcomes and performance-based functional assessments in both study arms, with a slight superiority in the TKA arm. Total weight loss % was higher in bariatric surgery patients (28.7%, P < 0.0001). Bariatric surgery resulted in 45 and 36% delays in TKA at 12 and 24 months, respectively, due to improved knee status. CONCLUSION/CONCLUSIONS:Knee function and mobility improved significantly in both study arms, with superiority in the Knee Injury and Osteoarthritis Outcome and Western Ontario and McMaster Universities Osteoarthritis Index scores in the TKA group. Improved knee function with surgical weight loss can be associated with up to a two-year delay in the need for TKA.

BACKGROUND:Management of severe acetabular bone loss during revision total hip arthroplasty (rTHA) remains challenging. Cup-cage constructs and custom triflange acetabular components are commonly used, but comparative outcomes remain poorly defined. METHODS:This meta-analysis was performed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. There were four electronic databases searched for studies published from 2015 to 2025 that reported outcomes of cup-cage or custom triflange reconstruction in patients who had Paprosky 2 to 3B acetabular defects. Indications for cup-cage and triflange constructs were recorded. Re-revision, periprosthetic joint infection (PJI), instability, and aseptic loosening were pooled using fixed- and random-effects models. Meta-regression was performed to adjust for acetabular defect severity. RESULTS:There were 18 studies comprising 808 revision THAs (293 cup-cage and 515 custom triflange) included. Across both reconstruction strategies, the most common indications were aseptic loosening and conversion after periprosthetic joint infection. The weighted mean follow-up was 5.8 years for cup-cage and 6.2 years for triflange reconstructions (P = 0.071). The cup-cage cohort had a higher proportion of Paprosky 3B defects than the triflange cohort (79.2 versus 71.8%, P < 0.001). After adjustment for acetabular defect severity, no differences in re-revision rates were observed between cup-cage and triflange constructs. Likewise, there were no differences in PJI, instability, or aseptic loosening between groups. CONCLUSIONS:Among patients undergoing rTHA with cup-cage or custom triflange reconstruction for Paprosky 2 to 3B defects, outcomes were equivalent across major failure modes after adjustment for bone loss severity. Neither construct demonstrated superior survivorship; therefore, implant selection should be individualized according to defect pattern, available resources, surgical goals, and surgeon preference rather than an expectation of differential clinical performance.

Young adults with hip pathology present a therapeutic challenge requiring careful consideration of treatment options that will affect decades of future function. Historically, the orthopedic community has maintained a strong preservation bias, often pursuing multiple preservation attempts before considering arthroplasty because of concerns about implant longevity. This narrative review critically examines current evidence regarding hip preservation surgery and total hip arthroplasty in young adults to inform evidence-based decision making. The literature reveals that successful hip preservation requires a narrow therapeutic window defined by preserved articular cartilage, accurate structural diagnosis, and appropriate patient selection. Clinical and imaging predictors, including joint space narrowing below 2 mm, Tönnis grade 2 or higher osteoarthritis, bipolar chondral damage, and mechanical symptoms, reliably identify patients unlikely to benefit from preservation. Concurrently, advances in bearing surfaces-particularly highly cross-linked polyethylene and ceramics-have dramatically improved arthroplasty outcomes, with contemporary data demonstrating 10-year survivorship exceeding 90% in patients younger than 55 years. Modern total hip arthroplasty delivers consistent pain relief and functional improvement that often exceeds preservation outcomes in appropriately indicated patients. This review proposes a decision-making framework emphasizing that treatment selection should be guided by objective disease characteristics rather than age-based algorithms, optimizing long-term outcomes while minimizing unnecessary morbidity.

PURPOSE/OBJECTIVE:Nonsteroidal anti-inflammatory drugs (NSAIDs) increase fluid retention and the risk of heart failure (HF). The NSAIDs are commonly used in total hip arthroplasty (THA) as part of a modern multimodal pain protocol, but the risk of selective cyclooxygenase-2 (COX-2)-preferential NSAIDs in THA for Type 2 diabetes mellitus (T2DM) patients, who have an increased risk for cardiac disease, is not well understood. This study aimed to compare rates of new-onset HF following THA in T2DM patients receiving perioperative meloxicam or celecoxib. METHODS:A retrospective review was conducted of 18,142 patients who underwent primary elective THA. Data included demographics, perioperative aspirin, meloxicam and celecoxib use, T2DM diagnosis, and development of new-onset postoperative HF. Cohorts were separated based on the presence of a T2DM diagnosis and use of meloxicam or celecoxib. Propensity-matching controlled for age, American Society of Anesthesiologists score, and perioperative aspirin use. Rates of HF within T2DM patients who utilized peri-THA meloxicam versus celecoxib were compared. RESULTS:Of patients who utilized meloxicam or celecoxib, T2DM patients experience new-onset postoperative HF at higher rates than non-diabetics (6.1 [T2DM] versus 2.8% [non-T2DM], P < 0.001). Within the T2DM patients, the patients who utilized celecoxib developed HF at higher rates than T2DM patients who utilized meloxicam (4.0 [meloxicam] versus 7.1% [celecoxib], P = 0.013). CONCLUSIONS:Patients who have T2DM experience a higher incidence of new-onset postoperative HF compared to non-diabetics following perioperative selective NSAID use for THA. Additionally, T2DM patients developed HF at a greater rate when treated with perioperative celecoxib versus meloxicam. Given that both agents were associated with HF events in this high-risk population, caution is warranted when prescribing selective NSAIDs in T2DM patients undergoing THA. Risk-benefit considerations and individualized perioperative pain management strategies should be carefully considered.

INTRODUCTION/BACKGROUND:Use of the direct anterior approach (DAA) in total hip arthroplasty (THA) has increased, with suggested benefits of faster recovery and less pain. However, consensus regarding the optimal approach is lacking. This study compared post-operative pain, functional recovery, and opioid use between DAA and posterior approach (PA) THA. METHODS:-tests. RESULTS: 0.001), but these small differences do not reflect clinical significance. MME comparison showed a trend towards decreased opioid consumption within the DAA cohort, but the clinical relevance of these differences is unknown. CONCLUSIONS:Pain, function, and opioid use were largely comparable between DAA and PA, with minor statistical differences unlikely to be clinically meaningful.

BACKGROUND:Hip resurfacing arthroplasty (HRA) is a femoral bone-preserving alternative to total hip arthroplasty (THA) for younger, active patients. However, complications such as fractures, loosening, and metal wear can require conversion to THA. In some cases, revision of both the acetabular and femoral components is required. METHODS:We conducted a retrospective review of 15 patients who underwent conversion of HRA to THA at a single, academic tertiary care centre between January 2011 and April 2024. Demographic data, surgical details, implant characteristics, and indications for conversion were collected. Postoperative outcomes including complications, reoperations, and revisions were investigated. Revision-free survival was estimated using Kaplan-Meier analysis. RESULTS: = 3). Dual-mobility (DM) constructs were used in 11 cases (73.3%). There were no dislocations. There was 1 90-day readmission due to persistent wound drainage which underwent debridement, antibiotics, and implant retention (DAIR) 14 days post-conversion. The average follow-up duration after the conversion procedure was 6.1 years. Kaplan-Meier analysis demonstrated 93% revision-free survival at one-year, which remained stable through 13 years. CONCLUSIONS:In this study of 15 both-component HRA conversions, we observed 93% revision-free survivorship at mid-term follow-up. While the small cohort size limits definitive conclusions, our findings suggest that revision of the acetabulum during conversion, particularly with dual-mobility constructs, may be an effective strategy to mitigate instability and manage metal-on-metal failure in appropriate patients. Further research with larger cohorts is warranted to confirm our findings.

BACKGROUND:Robotic and navigation-assisted total knee arthroplasty (TKA) systems aim to optimize surgical performance; however, their influence on the speed of functional recovery remains unclear. This study compared the time to achieve a minimal clinically important difference (MCID) among patients undergoing robotic-assisted (RA), navigation-assisted (NA), and conventional TKA using Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS-JR) questionnaires. METHODS:This retrospective cohort study included patients undergoing primary TKA for osteoarthritis at a tertiary academic center from July 2017 to July 2024. Inclusion required preoperative and postoperative KOOS-JR scores within 12 months of surgery. Exclusion criteria were non-osteoarthritis indications, bilateral procedures, or revision within one year. The MCID was defined using both anchor-based and distribution-based methods. The time to MCID was analyzed using multivariable interval-censored accelerated failure time models, accounting for clinical and demographic variables and the operating surgeon. A total of 2,002 patients met the inclusion criteria: 433 (21.6%) underwent RA-TKA, 713 (35.6%) NA-TKA, and 856 (42.8%) conventional TKA. RESULTS:Both technology-assisted approaches were associated with faster MCID achievement compared to conventional TKA. Using distribution-based thresholds, NA-TKA achieved MCID 29% faster (time ratio [TR] = 0.71, 95% confidence interval (CI): 0.58 to 0.88, P = 0.002) and RA-TKA 26% faster (TR = 0.74, 95% CI: 0.57 to 0.95, P = 0.018), with covariate-standardized estimated median times of 19.9, 20.7, and 28.0 days, respectively. Using anchor-based thresholds, NA-TKA achieved MCID 27% faster (TR = 0.73, 95% CI: 0.57 to 0.95, P = 0.017) and RA-TKA 26% faster (TR = 0.74, 95% CI: 0.55 to 1.00, P = 0.050), with corresponding median times of 52.8, 53.5, and 71.9 days. The one-year MCID attainment rates were similar across all techniques (P > 0.6 for both definitions). CONCLUSIONS:Both RA-TKA and NA-TKA were associated with 26 to 29% faster achievement of clinically meaningful improvement compared with conventional TKA, corresponding to approximately seven to 19 fewer days to reach MCID, despite similar one-year attainment rates. Prospective multicenter studies are needed to validate these results and determine whether accelerated recovery translates to advantages in quality of life, healthcare utilization, and patient satisfaction.

INTRODUCTION/BACKGROUND:An extended trochanteric osteotomy (ETO) is used in complex cases to enhance access to the femoral canal and aid implant and cement removal during revision total hip arthroplasty (RTHA). However, there is no consensus regarding postoperative rehabilitation protocols. The aim of this study was to assess the efficacy and safety of immediate weight-bearing (WB) protocols in patients undergoing ETO during RTHA. METHODS:A multicenter retrospective review was conducted at two academic medical centers between 2014 and 2021 to identify patients undergoing an ETO during RTHA with a minimum 1-year follow-up. Thirty-nine patients underwent an immediate WB protocol postoperatively. Union rates, ambulatory status, 90-day orthopaedic-related complications, revision surgeries, revisions, and Hip Disability and Osteoarthritis Outcome Score Joint Replacement (HOOS JR) scores were collected. RESULTS:Fifty-three patients were included in the final analysis. The average follow-up time was 15.8 ± 20.4 months, with a mean age of 63.7 ± 11.5 years. Bony union was achieved in 46 patients (86.8%). The mean earliest time to union was 4.2 ± 5.4 months. Average HOOS JR scores significantly improved from preoperative to 1-year follow-up (mean 16.4 ± 4.1 vs 3.5 ± 4.2), P ≤ 0.000001). At the final follow-up, ambulatory status improved, with fewer patients kept as non-weight bearing (11 (21.6%) versus 7 (15.2%)). Two complications (3.8%) due to deep infection, 5 revision surgeries (9.4%), and 6 revisions (11.0%) were observed within 90 days. CONCLUSION/CONCLUSIONS:Most patients who underwent ETO during RTHA and were placed on an immediate WB protocol achieved union at 4.2 months on average. HOOS JR scores improved as early as 2 weeks. More importantly, a greater proportion of patients experienced an improved ambulatory status at the final follow-up. These findings suggest that an immediate WB protocol-particularly WBAT-may be effective and safely implemented in patients undergoing an ETO during RTHA. LEVEL OF EVIDENCE/METHODS:Level III retrospective cohort comparison study.

BACKGROUND:Nonmodular dual mobility (DM) articulations in total hip arthroplasty (THA) aim to reduce dislocations through a large outer bearing diameter while minimizing wear via a smaller inner bearing where most motion occurs. Although routine use remains uncommon in the United States, this construct may protect against dislocation. This study aimed to evaluate clinical outcomes of a cementless, nonmodular DM acetabular cup at a mean follow-up of two years. METHODS:We conducted a single-arm retrospective review of 604 primary, elective THAs using a cementless nonmodular DM acetabular cup between April 2017 and August 2024 at a single health system with at least 90 days of follow-up. All surgeries were performed by a single hip surgeon via posterior approach. Cases were planned using digital templating and performed with manual instruments without enabling technology. Clinical outcomes were collected, including 90-days readmission and revision rates, reasons for readmission and revision, and dislocation rates. RESULTS:At a mean follow-up of 2.0 years (range, 0.25 to 8.0), all-cause and aseptic acetabular cup implant survivorship was 99.8%. There were six revisions during the study period. There was one acetabular component (0.2%) that was revised due to cup dissociation from the pelvis. The remaining revisions included two for periprosthetic femoral fracture (0.3%), one for femoral loosening (0.2%), and two for acute periprosthetic joint infection (0.3%), none of which involved revision of the acetabular cup. There were no dislocations observed, and no patients required revision for instability. CONCLUSIONS:Cementless nonmodular DM acetabular cups offered excellent clinical outcomes in primary THA at a mean follow-up of 2.0 years, with no observed dislocations in 604 cases and high implant survivorship. These findings support the use of nonmodular DM implants as a viable option to achieve THA implant stability and durable fixation even when using a posterior approach without enabling technology.